134 related articles for article (PubMed ID: 35781785)
1. Clinical course of Coronavirus Disease-19 in patients with haematological malignancies is characterized by a longer time to respiratory deterioration compared to non-haematological ones: results from a case-control study.
Oliva A; Curtolo A; Volpicelli L; Cancelli F; Borrazzo C; Cogliati Dezza F; Marcelli G; Gavaruzzi F; Di Bari S; Ricci P; Turriziani O; Mastroianni CM; Venditti M
Infection; 2022 Oct; 50(5):1373-1382. PubMed ID: 35781785
[TBL] [Abstract][Full Text] [Related]
2. Outcome of COVID-19 patients with haematological malignancies after the introduction of vaccination and monoclonal antibodies: results from the HM-COV 2.0 study.
Oliva A; Cogliati Dezza F; Petrucci F; Romani FE; Morviducci M; Mirabelli FM; Cancelli F; Valeriani E; Marcelli G; Pugliese F; Turriziani O; Ricci P; Venditti M; Palange P; Mastroianni CM
Clin Exp Med; 2023 Oct; 23(6):2275-2285. PubMed ID: 36867292
[TBL] [Abstract][Full Text] [Related]
3. Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies.
Sanchez-Pina JM; Rodríguez Rodriguez M; Castro Quismondo N; Gil Manso R; Colmenares R; Gil Alos D; Paciello ML; Zafra D; Garcia-Sanchez C; Villegas C; Cuellar C; Carreño-Tarragona G; Zamanillo I; Poza M; Iñiguez R; Gutierrez X; Alonso R; Rodríguez A; Folgueira MD; Delgado R; Ferrari JM; Lizasoain M; Aguado JM; Ayala R; Martinez-Lopez J; Calbacho M
Eur J Haematol; 2020 Nov; 105(5):597-607. PubMed ID: 32710500
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
5. Regional outcomes of severe acute respiratory syndrome coronavirus 2 infection in hospitalised patients with haematological malignancy.
Booth S; Willan J; Wong H; Khan D; Farnell R; Hunter A; Eyre T; Katz H; Dungarwalla M; Chen L; Browning J; Polzella P; Gray N; Neelakantan P; Dhillon EK; Dutton D; Sternberg A; Prideaux S; Collins GP; Peniket A
Eur J Haematol; 2020 Oct; 105(4):476-483. PubMed ID: 32544294
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 infection among patients with haematological disorders: Severity and one-month outcome in 66 Danish patients in a nationwide cohort study.
Glenthøj A; Jakobsen LH; Sengeløv H; Ahmad SA; Qvist K; Rewes A; Poulsen CB; Overgaard UM; Mølle I; Severinsen MT; Strandholdt CN; Maibom J; Kodahl AR; Ryg J; Ravn P; Johansen IS; Helsø SN; Jensen-Fangel S; Kisielewicz J; Wiese L; Helleberg M; Kirk O; Clausen MR; Frederiksen H
Eur J Haematol; 2021 Jan; 106(1):72-81. PubMed ID: 32939853
[TBL] [Abstract][Full Text] [Related]
7. Mortality and clinical outcomes following SARS-CoV-2 infection among individuals with haematological malignancies: A Danish population-based cohort study.
Lund LC; Rahbek MT; Brown P; Obel N; Hallas J; Frederiksen H
Eur J Haematol; 2023 Dec; 111(6):946-950. PubMed ID: 37740535
[TBL] [Abstract][Full Text] [Related]
8. Clinical profile and outcome of COVID-19 in haematological malignancies: experience from tertiary care centre in India.
Gupta A; Desai N; Sanjeev ; Chauhan P; Nityanand S; Hashim Z; Gupta M
Ann Hematol; 2022 Jan; 101(1):69-79. PubMed ID: 34559278
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
10. COVID-19 in children with haematological malignancies.
Millen GC; Arnold R; Cazier JB; Curley H; Feltbower R; Gamble A; Glaser A; Grundy RG; Kirton L; Lee LYW; McCabe MG; Palles C; Phillips B; Stiller CA; Varnai C; Kearns P
Arch Dis Child; 2022 Feb; 107(2):186-188. PubMed ID: 34301621
[TBL] [Abstract][Full Text] [Related]
11. Impact of neutropenia on the clinical outcomes of Staphylococcus aureus bacteremia in patients with hematologic malignancies: a 10-year experience in a tertiary care hospital.
Ryu BH; Lee SC; Kim M; Eom Y; Jung J; Kim MJ; Sung H; Kim MN; Kim SH; Lee SO; Choi SH; Woo JH; Kim YS; Chong YP
Eur J Clin Microbiol Infect Dis; 2020 May; 39(5):937-943. PubMed ID: 31925572
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 infection in patients with haematological malignancies: A single-centre survey in the latest Omicron wave in China.
Zhu X; Jiang Q; Lu J; Sun Y; Zhao X; Yang S; Tang F; Yu W; Zhao T; Liu X; Jia J; Duan W; Hu L; Wang J; Liu Y; Peng N; Dou X; Ma R; Fu Q; Wang H; Liu K; Huang X; Jiang H
Br J Haematol; 2023 Jul; 202(1):31-39. PubMed ID: 37092433
[TBL] [Abstract][Full Text] [Related]
13. Australia and New Zealand consensus position statement: use of COVID-19 therapeutics in patients with haematological malignancies.
Campbell A; Teh B; Mulligan S; Ross DM; Weinkove R; Gilroy N; Gangatharan S; Prince HM; Szer J; Trotman J; Lane S; Dickinson M; Quach H; Enjeti AK; Ku M; Gregory G; Hapgood G; Ho PJ; Cochrane T; Cheah C; Greenwood M; Latimer M; Berkahn L; Wight J; Armytage T; Diamond P; Tam CS; Hamad N
Intern Med J; 2024 Feb; 54(2):328-336. PubMed ID: 38146232
[TBL] [Abstract][Full Text] [Related]
14. Association between prolonged corticosteroids use in COVID-19 and increased mortality in hospitalized patients: a retrospective study with inverse probability of treatment weighting analysis.
Viana MV; Pellegrini JAS; Perez AV; Schwarz P; da Silva D; Teixeira C; Gazzana MB; Rech TH
Crit Care; 2023 Apr; 27(1):143. PubMed ID: 37061719
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics and outcomes of patients with haematologic malignancies and COVID-19 suggest that prolonged SARS-CoV-2 carriage is an important issue.
Arcani R; Colle J; Cauchois R; Koubi M; Jarrot PA; Jean R; Boyer A; Lachamp J; Tichadou A; Couderc AL; Farnault L; Costello R; Venton G; Kaplanski G
Ann Hematol; 2021 Nov; 100(11):2799-2803. PubMed ID: 34518918
[TBL] [Abstract][Full Text] [Related]
16. Nosocomial outbreak of SARS-CoV-2 infection in a haematological unit - High mortality rate in infected patients with haematologic malignancies.
Biernat MM; Zińczuk A; Biernat P; Bogucka-Fedorczuk A; Kwiatkowski J; Kalicińska E; Marciniak D; Simon K; Wróbel T
J Clin Virol; 2020 Sep; 130():104574. PubMed ID: 32769026
[TBL] [Abstract][Full Text] [Related]
17. Clinical features and outcomes of hospitalized COVID-19 patients in a low burden region.
Eleni M; Evangelia M; Eleftheria K; Vasilios V; Vana S; Vissaria S; Evangelos B; Ioannis K
Pathog Glob Health; 2021 Jun; 115(4):243-249. PubMed ID: 33645468
[TBL] [Abstract][Full Text] [Related]
18. Identification of risk factors for in-hospital death of COVID - 19 pneumonia -- lessions from the early outbreak.
Wang Z; Wang Z
BMC Infect Dis; 2021 Jan; 21(1):113. PubMed ID: 33494706
[TBL] [Abstract][Full Text] [Related]
19. Haematological malignancy in the intensive care unit: microbiology results and mortality.
van Beers EJ; Müller MC; Vlaar AP; Spanjaard L; van den Bergh WM;
Eur J Haematol; 2016 Sep; 97(3):271-7. PubMed ID: 26676382
[TBL] [Abstract][Full Text] [Related]
20. Outcome in critically ill medical patients treated with renal replacement therapy for acute renal failure: comparison between patients with and those without haematological malignancies.
Benoit DD; Hoste EA; Depuydt PO; Offner FC; Lameire NH; Vandewoude KH; Dhondt AW; Noens LA; Decruyenaere JM
Nephrol Dial Transplant; 2005 Mar; 20(3):552-8. PubMed ID: 15671075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
